This inventor holds 25 USPTO granted patents and 7 published patent applications, plus 1 CIPO patent and 15 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Sanofi, Aventis Pharma S.a., Sanofi-A Ventis Deutschland Gmbh. Active years: 2004-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Flöersheim, DE (2004)
- Florsheim, DE (2008 - 2009)
- Floersheim, DE (2008 - 2010)
- Flörsheim, DE (2010)
- Mainz, DE (2010 - 2014)
- Frankfurt-am-Main, DE (2013 - 2017)
Company Filing History:
14 out of 1,547 
4 out of 377 
4 out of 1,855 
Years Active: 2004-2026
Areas of Expertise:
Title: Innovations and Contributions of Sven Ruf in the Pharmaceutical Field
Introduction
Sven Ruf, located in Frankfurt am Main, Germany, is a prolific inventor with 23 patents to his name. His work predominantly revolves around pharmaceutical innovations, aiming to develop compounds that combat serious health issues. With a keen focus on advancing medical science, he has made substantial contributions that are recognized within the industry.
Latest Patents
One of Sven Ruf's significant inventions involves the development of 3-heteroaroylamino-propionic acid derivatives. These compounds, classified under a specific formula I, hold promise as valuable pharmaceutical active compounds. They serve as inhibitors of the protease cathepsin A, which are crucial for treating diseases such as atherosclerosis, heart failure, renal diseases, liver diseases, and various inflammatory diseases. His patent also describes the processes for the synthesis of these compounds, their intended applications, and the pharmaceutical compositions that comprise them.
Career Highlights
Throughout his career, Sven Ruf has collaborated with notable companies such as Sanofi and Aventis Pharma S.A. His tenure at these organizations has enabled him to leverage his expertise in pharmaceutical sciences, leading to groundbreaking innovations that address significant health challenges.
Collaborations
Sven has collaborated with esteemed colleagues, including Thorsten Sadowski and Herman Schreuder. These collaborations have played a pivotal role in advancing his research and enhancing the efficacy of the compounds he has developed. Working together, they have contributed to a better understanding of pharmaceutical development and applications.
Conclusion
Sven Ruf continues to be a valuable asset to the pharmaceutical innovation landscape. His extensive portfolio of patents, particularly in the area of therapeutic compounds, demonstrates his commitment to improving healthcare solutions. As he forges ahead in his research, the impact of his inventions is likely to resonate within both the scientific community and the broader healthcare industry.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile